How Centralized IBC Review Can Benefit Gene Therapy Research
Understand the risks and regulatory requirements for gene therapy research and how a biosafety review can benefit this type of research.
Local Versus Central IRBs: What’s the Difference?
Local IRBs and central IRBs are not really that different, although sIRB mandates have complicated things for local IRBs.
Virtual Symposium: Gene Therapy Research in the Age of COVID-19
The coronavirus pandemic has brought genetic research to the forefront. To address emerging issues, Advarra presents its first virtual symposium. Read more:
Keep in Touch: Tips for Working with a Single IRB for the First Time
Recent regulations and policies have many institutions establishing policies and processes for working with an external sIRB. Read more:
How Sites Can Prepare for COVID-19 Genetically Engineered Vaccine Studies
Is your site prepared to participate in COVID-19 vaccine research? Registering an IBC ahead of time gives you an advantage. Read more:
A Tale of Two Sites: The Power of Integrated Research Administration
Learn how institutions attract more studies from the the tale of two sites: one with an integrated research administration, and one without.
Reporting to the IRB: Unanticipated Device Effects (UADEs) in Medical Device Studies
What do the regulations say about unanticipated device effects and IRB reporting requirements? In this blog, Advarra addresses some frustrating gray areas.